COPD Remote Patient Monitoring Through Connected Devices

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

Managing Diagnosed COPD Patients Through Connected Devices to Provide Pulmonologists With Objective Data to Inform Treatment Decisions and Enable Exacerbation Intervention

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05271474
• Other study ID #: STUDY00003325
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 2022
• Est. completion date: August 2022

Study information

• Verified date: June 2022
• Source: Innovation Hub Enterprises
• Contact: Alvaro Velasquez, MD
• Phone: 404-686-2505
• Email: avelasq[@]emory.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a device study that will use a double-arm. It will integrate the ANNE ONE platform which continuously tracks enrolled COPD patients' vital signs and symptoms over the course of the study and digitally shares that data with providers for clinical interpretation, potential intervention and treatment decision making and will help evaluate the impact on participating patient's COPD Assessment Test (CAT) scores. Subjects will be recruited from Emory clinics and identified via a data pull based on clinical relevant codes. Letters will be sent out to eligible candidates and interested participants will contact the research team. The research team will consent them over the phone and mail the device to them; participants will be compensated.

Description:

Chronic obstructive pulmonary disease (COPD) is a diseases that causes airflow limitation and breathing-related problems, affecting approximately 16 million people in the U.S., most of which are aged 40 and above with a history of smoking. COPD causes acute exacerbations where a patient has worsening symptoms (increased shortness of breath, cough, or sputum production). Managing COPD presents many challenges, as patients struggle to adhere to their prescribed treatment plans. Digital platforms are gradually becoming more available to enable providers to help patients manage their condition. These platforms create objective transparency, lessening the need for patients to consciously track their COPD exacerbation events, enabling providers to proactively manage their patients' condition, and creating actionable reports for providers to review with their patients. Ultimately, connected devices present a strong opportunity to provide patients with appropriate care earlier in the patient journey, while enabling pulmonologists to deliver more customized management based on close to real time objective data.

The primary goal of this study is to evaluate the impact of the implementation of the ANNE ONE platform on patients with COPD's condition. This will be achieved by using the ANNE ONE platform to continuously track enrolled COPD patients' vital signs over the course of the study and digitally sharing that data with providers for clinical interpretation, potential intervention and treatment decision making. Interviews have been conducted with leading pulmonologists and staff at Emory Healthcare to understand what factors are considered when recommending a treatment pathway for a COPD patient, what the current workflow shortcomings are and how a new workflow using the ANNE ONE platform could effectively be integrated at a pulmonologist's office.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: August 2022
• Est. primary completion date: August 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Adults 40>years

• Have a formal diagnosis of COPD

• Must be able to understand and speak English in order to complete the survey questionnaires.

• They must be able and willing to download the ANNE ONE application on a smartphone.

• Have their COPD managed by a pulmonologist.

• Have the willingness and ability to commit to the study period and completion of the surveys.

Exclusion Criteria:

• Participants with a formal diagnosis of asthma will be excluded.

• Those who are unable to read and/or speak English

• Patients who exhibit physical or mental disability precluding the ability to provide informed consent will be excluded from the study.

• Those who are unable or unwilling to download the ANNE ONE application will also be excluded.

• Additionally, participant who are not willing or able to commit to the duration of the study will not be included.

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Device:
• ANNE ONE Platform
ANNE ONE is one most advanced digital platforms that are gradually becoming more available to enable providers to help patients manage their condition. It integrates soft and flexible sensors for comprehensive vital signs monitoring. This platform creates objective transparency by automatically recording data from the sensor on the patient, lessening the need for patients to consciously track their COPD exacerbation events, enabling providers to proactively manage their patients' condition, and creating actionable reports for providers to review with their patients.

Locations

Country	Name	City	State
United States	Emory University Hospital	Atlanta	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
Innovation Hub Enterprises

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Exacerbation of COPD episodes by Assessment Test (CAT) scores Changes	CRC will be responsible for collecting through patient-reported and electronic medical record (EMR)-reported (clinical notes and/or hospitalizations). Greater impact on COPD Assessment Test (CAT) scores (reduction of patient symptoms) compared to control group.	At baseline and at 16 weeks
Secondary	Number of exacerbations onset detected	Clinical Research Coordinators (CRC) will be responsible for collecting through patient-reported and electronical medical record reported (clinical notes and/or hospitalizations).Episodes will be counted and compared from Intervention Group vs Control group.	From baseline to study completion (16 weeks)
Secondary	Vital data: SpO2 drop >4%	Data from ANNE ONE sensors will be reviewed for SpO2 drops below 7-day rolling average by more than 4% for 2 consecutive days.	From baseline to study completion (16 weeks)
Secondary	Vital data: SpO2 drop <90%	Data from ANNE ONE sensors will be reviewed for SpO2 drops below 90% for 2 consecutive days.	From baseline to study completion (16 weeks)
Secondary	Vital data: FEV1	Data from ANNE ONE sensors will be reviewed for Forced expiratory volume in the first second (FEV1) drops below 7-day rolling average by more than 1.645 standard deviations for 2 consecutive days.	From baseline to study completion (16 weeks)
Secondary	Vital data: Respiratory Rate	Data from ANNE ONE sensors will be collected reviewed for respiratory rate increases 15% for 2 consecutive days above 7-day rolling average.	From baseline to study completion (16 weeks)
Secondary	Provider Satisfaction Scores	CRC will connect with pulmonologists throughout the pilot and provide a closing survey	Week 16
Secondary	Change in Patient Satisfaction Scores	CRC will distribute survey to patients, once at the end of the pilot to understand patient experience and adherence.	Week 16
Secondary	Number of Patient Emergency Visits	CRC will be responsible for patient history surveys, as well as coordinating an electronical medical record for the population. CRC will keep up with emergency visits for each subject and record these.	Week 16
Secondary	Number of Uncontrolled Flags	Number of events that the system shows as "irregular" readings	From baseline to study completion (16 weeks)
Secondary	Response to Flags	Number of response received by providers to flags in the system triggered by patient's irregular readings	From baseline to study completion (16 weeks)